Xenopat

Xenopat is a CRO specialising in preclinical oncology services, providing researchers and companies with cutting-edge tools for the development of new cancer therapies. Our models and technologies support decision-making not only in preclinical phases, but also in clinical trials and even post-commercialisation.

We offer a wide range of models tailored to our customers’ needs, from simpler systems such as cell-derived xenograft (CDX) and syngeneic models, to highly sophisticated models that closely mimic human biology and improve the success rate of cancer drug development. These include our extensive range of patient-derived xenograft (PDX) models and humanised murine models.

Beyond preclinical research, Xenopat also provides healthcare professionals and patients with advanced technology to support personalised treatment decisions. Our Orthoxenograft® (PDX) models, generated from a small fragment of a patient’s tumour, allows us to test multiple therapies in a highly predictive system – helping to identify the most effective treatment for each individual.